Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 public companies in the "Health services" industry, but how does it compare to its peers? We will compare Better Therapeutics to similar companies based on the strength of its earnings, profitability, analyst recommendations, dividends, institutional ownership, risk and valuation.
Institutional and Insider Ownership
7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by insiders. Comparatively, 21.6% of shares of all "Health services" companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Get Better Therapeutics alerts:Analyst Ratings
This is a summary of current ratings and price targets for Better Therapeutics and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 277 | 0 | 2.65 |
Profitability
This table compares Better Therapeutics and its peers' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
Earnings and Valuation
This table compares Better Therapeutics and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.70 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 27.18 |
Better Therapeutics' peers have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Better Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' peers have a beta of 1.19, meaning that their average share price is 19% more volatile than the S&P 500.
Summary
Better Therapeutics beats its peers on 8 of the 12 factors compared.
About Better Therapeutics
(Get Rating)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.